1. Cybersecurity attacks top ECRI list of health technology hazards for 2022

   News item 05 February 2022 Pages: 1 - 1

2. Dosing intervals affect risk of brolucizumab-related retinal disorders

   News item 05 February 2022 Pages: 2 - 2

3. EPVC suggests monitoring for signs of liver damage from MS drug, glatiramer acetate

   News item 05 February 2022 Pages: 3 - 3

4. Growing evidence reassuring for mRNA COVID-19 vaccines in pregnancy

   News item 05 February 2022 Pages: 4 - 4

5. Health Canada issues reminder of cardiac AEs associated with domperidone

   News item 05 February 2022 Pages: 5 - 5

6. No causal association between antidepressant use and youth suicide

   News item 05 February 2022 Pages: 6 - 6

7. Potential cross-allergic reaction from pholcodine and neuromuscular blocking agents

   News item 05 February 2022 Pages: 7 - 7

8. Santen recalls batch of ciclosporin eye drops in UK

   News item 05 February 2022 Pages: 8 - 8

9. Barriers and facilitators to registering ADRs in electronic health records

   Clinical study 05 February 2022 Pages: 9 - 9

10. TNF-α inhibitors increase risk of HBV reactivation if HBsAg-positive

    Clinical study 05 February 2022 Pages: 10 - 10

11. Torii strain-derived mumps vaccine: adverse events in Japan

    Clinical study 05 February 2022 Pages: 11 - 11

12. Younger males at greatest risk of myocarditis after mRNA-based COVID-19 vaccination

    Clinical study 05 February 2022 Pages: 12 - 12

13. Erratum to: Lamotrigine

    Case report 05 February 2022 Pages: 13 - 13

14. Other adverse reaction research

    News item 05 February 2022 Pages: 14 - 14

15. Adalimumab/apremilast

    Case report 05 February 2022 Pages: 15 - 15

16. Adalimumab/methotrexate

    Case report 05 February 2022 Pages: 16 - 16

17. Allopurinol/amoxicillin/clavulanic-acid

    Case report 05 February 2022 Pages: 17 - 17

18. Amezinium-metilsulfate/midodrine

    Case report 05 February 2022 Pages: 18 - 18

19. Amiodarone

    Case report 05 February 2022 Pages: 19 - 19

20. Amiodarone

    Case report 05 February 2022 Pages: 20 - 20

21. Amiodarone

    Case report 05 February 2022 Pages: 21 - 21

22. Amlodipine/dobutamine/norepinephrine

    Case report 05 February 2022 Pages: 22 - 22

23. Amoxicillin

    Case report 05 February 2022 Pages: 23 - 23

24. Amoxicillin/clavulanic-acid/clarithromycin/dexamethasone

    Case report 05 February 2022 Pages: 24 - 24

25. Amoxicillin/clavulanic-acid/dexamethasone/piperacillin/tazobactam

    Case report 05 February 2022 Pages: 25 - 25

26. Amoxicillin/clavulanic-acid/lamotrigine

    Case report 05 February 2022 Pages: 26 - 26

27. Amphotericin-B-liposomal/heparin

    Case report 05 February 2022 Pages: 27 - 27

28. Anti-cancer drugs

    Case report 05 February 2022 Pages: 28 - 28

29. Anti-CD19-CAR-transduced-T-cells/antineoplastics

    Case report 05 February 2022 Pages: 29 - 29

30. Anti-infectives

    Case report 05 February 2022 Pages: 30 - 30

31. Anti-inflammatories

    Case report 05 February 2022 Pages: 31 - 31

32. Anti-inflammatories/factor-VIII/immunosuppressants

    Case report 05 February 2022 Pages: 32 - 32

33. Antibacterials

    Case report 05 February 2022 Pages: 33 - 33

34. Antibacterials/Vitamin-K

    Case report 05 February 2022 Pages: 34 - 34

35. Antineoplastics

    Case report 05 February 2022 Pages: 35 - 35

36. Antineoplastics

    Case report 05 February 2022 Pages: 36 - 36

37. Antineoplastics

    Case report 05 February 2022 Pages: 37 - 37

38. Antineoplastics

    Case report 05 February 2022 Pages: 38 - 38

39. Antineoplastics

    Case report 05 February 2022 Pages: 39 - 39

40. Antineoplastics

    Case report 05 February 2022 Pages: 40 - 40

41. Antineoplastics

    Case report 05 February 2022 Pages: 41 - 41

42. Antineoplastics

    Case report 05 February 2022 Pages: 42 - 42

43. Antineoplastics

    Case report 05 February 2022 Pages: 43 - 43

44. Antineoplastics/immunosuppressants

    Case report 05 February 2022 Pages: 44 - 44

45. Antineoplastics/immunosuppressants

    Case report 05 February 2022 Pages: 45 - 45

46. Antituberculars

    Case report 05 February 2022 Pages: 46 - 46

47. Apixaban/dexamethasone/remdesivir

    Case report 05 February 2022 Pages: 47 - 47

48. Ascorbic-acid/ozone

    Case report 05 February 2022 Pages: 48 - 48

49. Aspirin/immune-globulin

    Case report 05 February 2022 Pages: 49 - 49

50. Avapritinib

    Case report 05 February 2022 Pages: 50 - 50